PURA - Pharmaceutical Advancements in Medicinal Marijuana Continue to Evolve While Producing Higher Quality Cannabinoid Extra...
June 23 2017 - 10:03AM
InvestorsHub NewsWire
PALM BEACH, Florida, June 22, 2017 /PRNewswire/ -
Latest research and
development in the medicinal cannabis market is helping industry
leaders identify breakthroughs and significant discoveries for
developing new patents and therapies for various applications
targeting diseases including forms of cancer and rare conditions.
Cannabis companies in the markets this week with developments
include: Puration, Inc. (OTC: PURA), GW Pharmaceuticals plc
(NASDAQ: GWPH), CV Sciences Inc. (OTC: CVSI), 22ndCentury Group
Inc. (NASDAQ: XXII) and PotNetwork Holding Inc.
(OTC: POTN)
Puration, Inc. (OTC: PURA) today announced the Company has entered
into a letter of intent agreement to acquire First Choice Nursery
which has an existing twenty-five greenhouse facility. The
company has the opportunity to expand to an additional 400
irrigated greenhouse pads ready for buildout. Puration has a
U.S. Patented Cannabis Extraction process licensed from NCM
Biotech. The license of the process to Puration is the first
and only license NCM Biotech has executed. R&D with NCM
Biotech's patented process has demonstrated a high potential for
bringing FDA approved pharmaceutical products to market for the
treatment of multiple neurological disorders and cancer. NCM
Biotech's medical advisory team includes John N. Gaitanis,
MD., Director of Child Neurology at Tufts Medical Center/Floating
Hospital for Children; Lloyd R. Saberski, M.D., Associate
Professor of Anesthesiology and Chronic Pain Management, Yale
University and John McMichael, Ph.D., President and CEO
Beech Tree Labs.
Puration's NCM Biotech Extractions Compared to GW
Pharmaceutical (GWPH) –
"I have received doctor feedback from more than one of our research
initiatives that extracts coming from NCM Biotech's patented
process are superior in purity and quality to any other available
cannabis extracts," said Frederick Ferri, CEO and Founder of
NCM Biotech. "Some feedback has specifically indicated that a
number of our candidate pharmaceutical products under development
have a greater efficacy potential than GW Pharmaceutical products
and candidate products."
Read this and more news for Puration at http://www.marketnewsupdates.com/news/pura.html.
$1 Million Annual Revenue Operation With Initial Expansion
Target to $16 Million - The pending acquisition
of First Choice Nursery is taking over what was a family owned
nursery operation. The projected $1 million in annual
revenue from the operation of 25 greenhouses will come primarily
from the sale of traditional greenhouse-grown flowers for use in
residential landscaping. The original nursery operation had a long
history that includes contracts with Lowes and Home
Depot. Puration and NCM Biotech plan to expand existing
University Research relationships to include a portion of the
greenhouse facility being utilized to develop a proprietary strain
of CBD. Puration will use proceeds from the balance of the
traditional nursery operation to expand the operation into its full
400 greenhouse potential.
In other industry developments and market activity:
GW Pharmaceuticals plc (NASDAQ: GWPH) closed up
at $104.72 on Wednesday with over 300,000 shares traded
by the market close. GW Pharmaceuticals announced
back in May that that The New England Journal of Medicine has
published results from a Phase 3 study of Epidiolex® (cannabidiol)
in children with Dravet syndrome. Epidiolex, GW's lead product
candidate and the potential first in a new category of
anti-epileptic drugs, is a liquid formulation of purified,
plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid,
which is being studied for the treatment of a number of rare,
severe pediatric-onset epilepsy disorders. In the study, Epidiolex
significantly reduced monthly convulsive seizure frequency compared
to placebo in highly treatment-resistant children when added to
existing treatment. Treatment with Epidiolex was generally well
tolerated, with a safety profile consistent with prior open label
experience.
CV Sciences Inc. (OTCQB: CVSI) finished Wednesday up slightly
at $0.241 by the market close. The company recently
announced that it held its pre-IND meeting with the U.S. Food and
Drug Administration (FDA) on June 15, 2017, to review its drug
development plan for CVSI-007, the Company's patent-pending product
for smokeless tobacco addiction therapy consisting of
nicotine-polacrilex chewing gum in combination with synthetic
cannabidiol (CBD). CV Sciences President and CEO Michael J.
Mona, Jr. commented, "Our pre-IND meeting with the FDA was
very constructive and provided the Company with a favorable
development roadmap for this important combination drug
candidate."
22nd Century Group Inc. (NYSE: XXII) closed up slightly on Wednesday
at $1.81 trading over 700,000 shares by the market close.
The company recently announced that, together with
The University of Virginia (UVA), it has launched a
project aimed at utilizing novel varieties of industrial hemp to
clean up and reclaim abandoned mine lands and other polluted areas.
These polluted lands will be returned to productive use and
cultivation through a cost-effective, plant-based process known as
'phytoremediation.' 22nd Century has developed proprietary
hemp plants that are particularly well-suited for use in
phytoremediation.
PotNetwork Holding Inc. (OTC: POTN) recently announced that
its wholly-owned subsidiary, Diamond CBD, Inc., after reporting a
string of record breaking monthly revenues, reports once again that
it has surpassed projections yet again as the result of heightening
demand for its products. "To the surprise of many, our momentum has
not plateaued. Our continued upward trend in sales is the result of
an offering of an outstanding range of excellent products supported
by a determined, tireless and goal-oriented team. As we conclude a
succession of very successful trade show events, we continue to be
exceedingly pleased with the results."
Read the full release here: https://finance.yahoo.com/news/1-098-448-00-may-154200247.html
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party
publisher and news
dissemination service provider, which disseminates electronic
information through multiple online media channels. MNU is NOT
affiliated in any manner with any company mentioned
herein. MNU and its affiliated companies are a news
dissemination solutions provider and are NOT a registered
broker/dealer/analyst/adviser, holds no investment licenses and may
NOT sell, offer to sell or offer to buy any security. MNU's
market updates, news alerts and corporate profiles are NOT a
solicitation or recommendation to buy, sell or hold
securities. The material in this release is intended to be
strictly informational and is NEVER to be construed or interpreted
as research material. All readers are strongly urged to
perform research and due diligence on their own and consult a
licensed financial professional before considering any level of
investing in stocks. All material included herein is
republished content and details which were previously disseminated
by the companies mentioned in this release. MNU is not liable
for any investment decisions by its readers or
subscribers. Investors are cautioned that they may lose all or
a portion of their investment when investing in stocks. For
current services performed MNU has been compensated three
thousand nine hundred dollars for news coverage of the
current press release issued by Puration, Inc. by a non-affiliated
third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS
RELEASE.
This release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words
such as "may", "future", "plan" or "planned", "will" or "should",
"expected," "anticipates", "draft", "eventually" or "projected".
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company's annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and MNU undertakes no
obligation to update such statements.
Contact Information:
Media Contact email:
info@marketnewsupdates.com
+1(561)325-8757
SOURCE MarketNewsUpdates.com
CV Sciences (QB) (USOTC:CVSI)
Historical Stock Chart
From Aug 2024 to Sep 2024
CV Sciences (QB) (USOTC:CVSI)
Historical Stock Chart
From Sep 2023 to Sep 2024